GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 2,172 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 2,172 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total transaction of $141,592.68. Following the transaction, the chief executive officer owned 93,216 shares in the company, valued at approximately $6,076,751.04. This trade represents a 2.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Katherine Stueland also recently made the following trade(s):

• On Thursday, March 26th, Katherine Stueland sold 46,933 shares of GeneDx stock. The shares were sold at an average price of $63.17, for a total transaction of $2,964,757.61.
• On Monday, March 16th, Katherine Stueland sold 17,179 shares of GeneDx stock. The shares were sold at an average price of $76.80, for a total transaction of $1,319,347.20.
• On Wednesday, March 4th, Katherine Stueland sold 25,459 shares of GeneDx stock. The stock was sold at an average price of $78.61, for a total transaction of $2,001,331.99.

GeneDx Stock Performance

NASDAQ WGS traded up $2.49 during trading on Friday, reaching $65.38. The company’s stock had a trading volume of 591,523 shares, compared to its average volume of 727,660. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.34 and a current ratio of 2.46. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -87.17 and a beta of 2.17. GeneDx Holdings Corp. has a twelve month low of $55.17 and a twelve month high of $170.87. The business’s fifty day moving average price is $71.45 and its 200-day moving average price is $107.37.

GeneDx (NASDAQ:WGS) last announced its earnings results on Monday, February 23rd. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.03. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. The business had revenue of $120.99 million during the quarter, compared to the consensus estimate of $120.80 million. As a group, analysts anticipate that GeneDx Holdings Corp. will post 0.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC acquired a new stake in GeneDx in the 4th quarter valued at about $27,000. Jones Financial Companies Lllp lifted its holdings in shares of GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares in the last quarter. Ramirez Asset Management Inc. purchased a new stake in shares of GeneDx in the fourth quarter valued at about $33,000. Greenline Wealth Management LLC acquired a new stake in shares of GeneDx in the fourth quarter valued at approximately $33,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of GeneDx in the fourth quarter valued at approximately $35,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on WGS. Guggenheim reduced their target price on shares of GeneDx from $170.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Canaccord Genuity Group set a $100.00 price target on shares of GeneDx and gave the stock a “buy” rating in a research note on Monday, April 20th. Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a research report on Wednesday, January 21st. BTIG Research lowered their price objective on GeneDx from $200.00 to $170.00 and set a “buy” rating on the stock in a report on Tuesday, February 24th. Finally, Piper Sandler reiterated an “overweight” rating and set a $130.00 target price (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $134.17.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.